SRRK Scholar Rock Holding Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
• • New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
• • Strategic shift: Transitioning to global commercial-stage biotech; appointed new CEO and expanded U.S./European commercial teams (~50 employees)
• • Notable metric: Submitted BLA for apitegromab in SMA in Jan 2025; received FDA Priority Review and EMA MAA acceptance in March 2025
• • Unique fact: Apitegromab is first myostatin inhibitor with positive Phase 3 SAPPHIRE study outcome and plans to target additional indications including infants under 2 years and FSHD

Risk Factors

• • FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
• • Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
• • Supply chain risk: reliance on limited third-party manufacturers for materials, with potential interruptions or quality issues impacting clinical/commercial supplies
• • Competitive risk: dependence on continued availability of approved SMN-targeted treatments (e.g., nusinersen, risdiplam) for apitegromab trials; limited access could halt trials
• • Financial risk: ongoing net losses and urgent need for additional capital to fund development and commercialization of apitegromab, SRK-181, SRK-439

Management Discussion & Analysis

• • Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
• • R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
• • Apitegromab R&D costs rose 14.7% to $89.8M; SRK-181 decreased 75.8%, SRK-439 decreased 22.9%
• • Cash, cash equivalents, and securities $367.6M at 2025 YE, down $69.7M YoY; net cash used in operations $300.0M
• • Raised $91.7M from ATM stock sales, $50M from debt facility, $63.8M from warrant exercises in 2025
• • FDA CRL for apitegromab due to third-party fill-finish issues; resubmission pending resolution, Phase 2 trial in FSHD planned mid-2026
• • Management expects ongoing substantial expenses for R&D, commercialization, and infrastructure build ahead of potential apitegromab launch

What are the latest SRRK SEC filings in 2026?

Scholar Rock Holding Corp (SRRK) has filed a 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did SRRK file its most recent 10-K annual report?

Scholar Rock Holding Corp (SRRK) filed its most recent 10-K annual report on March 3, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view SRRK 10-Q quarterly reports?

Scholar Rock Holding Corp (SRRK)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every SRRK 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has SRRK filed recently?

Scholar Rock Holding Corp (SRRK)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find SRRK insider trading activity (Form 4)?

SignalX aggregates every SRRK Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does SRRK file with the SEC?

Scholar Rock Holding Corp (SRRK) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SRRK filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Scholar Rock Holding Corp (SRRK).

What is SRRK's SEC CIK number?

Scholar Rock Holding Corp (SRRK)'s SEC CIK (Central Index Key) number is 1727196. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1727196 to look up all SRRK filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find SRRK return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Scholar Rock Holding Corp (SRRK) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.